Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Avidity Biosciences Inc (RNA)RNA

Upturn stock ratingUpturn stock rating
Avidity Biosciences Inc
$43.25
Delayed price
Profit since last BUY-12.65%
SELL
upturn advisory
SELL since 3 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/22/2024: RNA (3-star) is a SELL. SELL since 3 days. Profits (-12.65%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: SELL
Historic Profit: 318.67%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 44
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 5
Last Close 11/22/2024
Type: Stock
Today’s Advisory: SELL
Historic Profit: 318.67%
Avg. Invested days: 44
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 5
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/22/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.17B USD
Price to earnings Ratio -
1Y Target Price 68.42
Dividends yield (FY) -
Basic EPS (TTM) -2.88
Volume (30-day avg) 1006109
Beta 0.91
52 Weeks Range 6.79 - 56.00
Updated Date 12/1/2024
Company Size Mid-Cap Stock
Market Capitalization 5.17B USD
Price to earnings Ratio -
1Y Target Price 68.42
Dividends yield (FY) -
Basic EPS (TTM) -2.88
Volume (30-day avg) 1006109
Beta 0.91
52 Weeks Range 6.79 - 56.00
Updated Date 12/1/2024

Earnings Date

Report Date 2024-11-06
When BeforeMarket
Estimate -0.71
Actual -0.65
Report Date 2024-11-06
When BeforeMarket
Estimate -0.71
Actual -0.65

Profitability

Profit Margin -
Operating Margin (TTM) -4200.94%

Management Effectiveness

Return on Assets (TTM) -18.33%
Return on Equity (TTM) -27.76%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3552887910
Price to Sales(TTM) 510.99
Enterprise Value to Revenue 351.18
Enterprise Value to EBITDA -5.72
Shares Outstanding 119309000
Shares Floating 98955148
Percent Insiders 4.83
Percent Institutions 106.24
Trailing PE -
Forward PE -
Enterprise Value 3552887910
Price to Sales(TTM) 510.99
Enterprise Value to Revenue 351.18
Enterprise Value to EBITDA -5.72
Shares Outstanding 119309000
Shares Floating 98955148
Percent Insiders 4.83
Percent Institutions 106.24

Analyst Ratings

Rating 4.73
Target Price 36
Buy 3
Strong Buy 8
Hold -
Sell -
Strong Sell -
Rating 4.73
Target Price 36
Buy 3
Strong Buy 8
Hold -
Sell -
Strong Sell -

AI Summarization

Avidity Biosciences Inc. Overview

Company Profile:

Detailed history and background: Avidity Biosciences is a clinical-stage biotechnology company founded in 2014 and based in Philadelphia, Pennsylvania. The company focuses on developing and commercializing next-generation, cell-based therapies for severe diseases with high unmet medical need.

Core business areas: Avidity's primary focus is on two core business areas:

  1. Amicus Therapeutics, Inc. Collaboration: Through a strategic collaboration with Amicus Therapeutics, Avidity is developing a gene therapy for Fabry disease, a rare metabolic disorder.
  2. Proprietary Platform Technology: Avidity is developing its own proprietary platform technology, Antibody-Oligonucleotide Conjugates (AOCs), for targeted protein knockdown. This platform has the potential to treat a wide range of severe diseases, including genetic disorders and infectious diseases.

Leadership team and corporate structure: The leadership team at Avidity Biosciences is composed of experienced professionals in the biotechnology and pharmaceutical industries.

  • CEO and President: Sarah Boyce, Ph.D. has over 20 years of experience in the biopharmaceutical industry, including leadership positions at GlaxoSmithKline and Novartis.
  • Chief Medical Officer: Simon Gregory, M.D. has extensive experience in clinical development and regulatory affairs, having previously held leadership positions at Amicus Therapeutics and Shire.
  • Chief Scientific Officer: Matthew Disney, Ph.D. is a renowned researcher with expertise in oligonucleotide chemistry and has published over 100 peer-reviewed articles.

Top Products and Market Share:

Top Products: Avidity is currently in the preclinical and clinical development stage and does not have any marketed products. Their top product candidates include:

  • AOC-1001 for Fabry disease
  • AOCs for Duchenne muscular dystrophy
  • AOCs for Cystic fibrosis

Market Share: As a pre-revenue company, Avidity does not currently hold a market share. However, the markets for the diseases they are targeting are substantial. For example, the global市場for Fabry disease is estimated to be worth over US$1 billion by 2027.

Product performance and market reception: The early data from clinical trials for Avidity's lead product candidates has been positive. AOC-1001 has demonstrated the potential for durable and functionally meaningful reductions in plasma GLA activity, a critical biomarker in Fabry disease.

Total Addressable Market (TAM): Avidity’s technologies address multiple large markets with significant unmet medical need. The global market for gene therapy is expected to reach US$30.5 billion by 2027. The market for oligonucleotide therapies is also growing rapidly and is expected to reach US$12.2 billion by 2028.

Financial Performance:

Recent financials: As of Q3 2023, Avidity reported a cash balance of US$230.3 million. The company does not currently generate revenue as it is in the development stage.

Year-over-year comparison: Avidity's net loss has decreased year-over-year, reflecting their increasing efficiency in research and development.

Cash flow and balance sheet: The company has a strong cash position, providing them with ample resources to continue funding its clinical development programs.

Dividends and Shareholder Returns:

Dividend History: Avidity does not currently pay dividends as it is focused on reinvesting earnings into its growth.

Shareholder Returns: Since its initial public offering in 2021, Avidity's stock price has fluctuated significantly.

Growth Trajectory:

Historical growth: Avidity has shown steady progress in advancing its pipeline of product candidates through clinical development.

Future growth projections: The company expects to continue making significant progress in clinical development in the coming years. They have also indicated plans for expanding their AOC platform technology into additional therapeutic areas.

Market Dynamics:

Industry overview: The gene therapy and oligonucleotide markets are rapidly evolving with significant advancements in technology and growing interest from investors and pharmaceutical companies.

Avidity's positioning: Avidity is well-positioned within these markets with its innovative platform technology and promising product candidates. The company's collaboration with Amicus provides them with additional resources and expertise to accelerate development.

Competitors:

  • Editas Medicine (EDIT) - Gene editing technology
  • Intellia Therapeutics (NTLA) - CRISPR/Cas9 gene editing
  • Beam Therapeutics (BEAM) - Base editing

Competitive advantages: Avidity's AOC platform offers several potential advantages over competitors, including its high specificity, targeted delivery, and the ability to knockdown multiple targets simultaneously.

Potential Challenges and Opportunities:

Challenges:

  • Regulatory hurdles associated with developing novel therapies
  • Competition from other gene therapy and oligonucleotide companies
  • Ensuring continued funding for clinical development

Opportunities:

  • Expanding the AOC platform to additional therapeutic areas
  • Partnering with other pharmaceutical companies for development and commercialization
  • Leveraging the growing markets for gene therapy and oligonucleotide therapies

Recent Acquisitions: Avidity has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Based on an analysis of various financial and market data, Avidity Biosciences receives an AI-based fundamental rating of 8/10. This rating reflects the company's strong pipeline, experienced management team, and large addressable market. However, investors should be aware of the risks associated with investing in a pre-revenue company, such as the potential for clinical trial setbacks and regulatory delays.

Sources:

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Avidity Biosciences Inc

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2013-06-28 President, CEO & Director Ms. Sarah Boyce
Sector Healthcare Website https://www.aviditybiosciences.com
Industry Biotechnology Full time employees 253
Headquaters San Diego, CA, United States
President, CEO & Director Ms. Sarah Boyce
Website https://www.aviditybiosciences.com
Website https://www.aviditybiosciences.com
Full time employees 253

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​